What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
Mark C. Petrie mostly deals with Internal medicine, Heart failure, Cardiology, Ejection fraction and Randomized controlled trial.
His Internal medicine research incorporates elements of Diabetes mellitus, Endocrinology and Type 2 diabetes.
His Heart failure study combines topics from a wide range of disciplines, such as Epidemiology, Heart disease, Intensive care medicine and Hazard ratio.
His work focuses on many connections between Cardiology and other disciplines, such as Surgery, that overlap with his field of interest in Etiology.
His Ejection fraction research is multidisciplinary, relying on both Candesartan, Cause of death and Atrial fibrillation.
His studies in Transplantation integrate themes in fields like Heart Function Tests, Cardiovascular agent, Cardiac contractility modulation and Acute decompensated heart failure.
His most cited work include:
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. (9345 citations)
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (1150 citations)
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (876 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Cardiology, Heart failure, Ejection fraction and Myocardial infarction.
His work on Internal medicine is being expanded to include thematically relevant topics such as Diabetes mellitus.
His research in Cardiology intersects with topics in Magnetic resonance imaging, Surgery and Clinical trial.
His work investigates the relationship between Heart failure and topics such as Intensive care medicine that intersect with problems in Epidemiology.
His Ejection fraction research integrates issues from Empagliflozin, Sudden death, Blood pressure and Dapagliflozin.
His Conventional PCI study integrates concerns from other disciplines, such as Interventional cardiology and Angioplasty.
He most often published in these fields:
- Internal medicine (94.43%)
- Cardiology (77.22%)
- Heart failure (69.37%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (94.43%)
- Heart failure (69.37%)
- Cardiology (77.22%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Heart failure, Cardiology, Ejection fraction and Myocardial infarction.
Mark C. Petrie integrates Internal medicine and In patient in his studies.
His study explores the link between Heart failure and topics such as Comorbidity that cross with problems in COPD.
His Cardiology study combines topics in areas such as Magnetic resonance imaging and Cardiac magnetic resonance imaging.
His Ejection fraction research also works with subjects such as
- Empagliflozin and related Canagliflozin,
- Diabetes mellitus which intersects with area such as Disease.
The study incorporates disciplines such as Stroke and Clinical endpoint in addition to Myocardial infarction.
Between 2019 and 2021, his most popular works were:
- Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes (76 citations)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial (66 citations)
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. (46 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Myocardial infarction
His scientific interests lie mostly in Internal medicine, Heart failure, Ejection fraction, Cardiology and Dapagliflozin.
Internal medicine is represented through his Clinical endpoint, Randomized controlled trial, Adverse effect, ACE inhibitor and Meta-analysis research.
His research integrates issues of Valsartan, Presentation and Hazard ratio in his study of Heart failure.
The various areas that Mark C. Petrie examines in his Hazard ratio study include Decompensation, Proportional hazards model, Paradigm hf and Atrial fibrillation.
His work carried out in the field of Ejection fraction brings together such families of science as MEDLINE, Diabetes mellitus, Type 2 Diabetes Mellitus, Quality of life and Disease.
Mark C. Petrie has included themes like Empagliflozin, Magnetic resonance imaging and Microcirculation in his Cardiology study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
